TRCT
CSTL icon

Tower Research Capital (TRC)’s Castle Biosciences CSTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.4K Sell
1,604
-409
-20% -$13.4K ﹤0.01% 2957
2025
Q4 		$78.3K Sell
2,013
-1,653
-45% -$53.3K ﹤0.01% 2117
2025
Q3 		$83.5K Buy
3,666
+875
+31% +$17.8K ﹤0.01% 2146
2025
Q2 		$57K Buy
2,791
+2,009
+257% +$37.2K ﹤0.01% 2854
2025
Q1 		$15.7K Sell
782
-10,483
-93% -$260K ﹤0.01% 3209
2024
Q4 		$300K Buy
11,265
+7,524
+201% +$229K 0.01% 1411
2024
Q3 		$107K Sell
3,741
-205
-5% -$5.22K ﹤0.01% 2178
2024
Q2 		$85.9K Buy
3,946
+3,756
+1,977% +$83.7K ﹤0.01% 2684
2024
Q1 		$4.21K Sell
190
-5,153
-96% -$112K ﹤0.01% 4714
2023
Q4 		$115K Buy
5,343
+4,366
+447% +$76.8K ﹤0.01% 2541
2023
Q3 		$16.5K Sell
977
-10
-1% -$175 ﹤0.01% 3555
2023
Q2 		$13.5K Buy
987
+362
+58% +$7.33K ﹤0.01% 3758
2023
Q1 		$14K Buy
625
+160
+34% +$3.91K ﹤0.01% 3873
2022
Q4 		$11K Sell
465
-1,356
-74% -$31.4K ﹤0.01% 3800
2022
Q3 		$47K Buy
1,821
+691
+61% +$19.4K ﹤0.01% 3210
2022
Q2 		$25K Sell
1,130
-1,713
-60% -$39.8K ﹤0.01% 3549
2022
Q1 		$128K Buy
2,843
+2,400
+542% +$99.2K ﹤0.01% 2029
2021
Q4 		$19K Sell
443
-2,236
-83% -$117K ﹤0.01% 3709
2021
Q3 		$178K Sell
2,679
-1,769
-40% -$124K ﹤0.01% 1921
2021
Q2 		$326K Buy
4,448
+606
+16% +$40K 0.01% 1528
2021
Q1 		$263K Sell
3,842
-5,016
-57% -$377K ﹤0.01% 1774
2020
Q4 		$595K Buy
8,858
+455
+5% +$24.7K 0.02% 867
2020
Q3 		$432K Buy
8,403
+6,295
+299% +$280K ﹤0.01% 1844
2020
Q2 		$79K Buy
+2,108
New +$72K ﹤0.01% 2654
2020
Q1 		– Sell
-2,476
Closed -$85K – 3168
2019
Q4 		$85K Buy
+2,476
New +$60.5K 0.01% 1033

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s CSTL Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Castle Biosciences (CSTL) stake by 20% in Q1 2026, selling an estimated $13.4K and leaving 1,604 shares worth $39.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2957.

Tower Research Capital (TRC) first reported a position in CSTL in Q4 2019 and has held it in 25 quarters since. The position peaked at $595K in Q4 2020. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Tower Research Capital (TRC) held 1,604 shares of Castle Biosciences worth $39.4K as of Q1 2026.
  • Tower Research Capital (TRC) sold 409 Castle Biosciences shares in Q1 2026, an estimated $13.4K.
  • Castle Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2957 holding.
  • Tower Research Capital (TRC) first reported a position in Castle Biosciences in Q4 2019 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Castle Biosciences position peaked at $595K in Q4 2020.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.